DaVita HealthCare Partners Inc
$ 183.77
1.72%
07 Aug - close price
- Market Cap 11,795,278,000 USD
- Current Price $ 183.77
- High / Low $ 183.87 / 176.59
- Stock P/E 15.31
- Book Value -11.96
- EPS 12.00
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.88 %
- 52 Week High 247.49
- 52 Week Low 101.00
About
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Analyst Target Price
$220.71
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-02-02 | 2025-10-29 | 2025-08-05 | 2025-05-12 | 2025-02-13 | 2024-10-29 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-07 |
| Reported EPS | 4.02 | 2.87 | 3.4 | 2.51 | 2.95 | 2 | 2.24 | 2.59 | 2.59 | 2.38 | 1.87 | 2.85 |
| Estimated EPS | 4.01 | 2.33 | 3.19 | 3.17 | 2.75 | 2.02 | 2.13 | 2.72 | 2.63 | 1.92 | 1.66 | 2.04 |
| Surprise | 0.01 | 0.54 | 0.21 | -0.66 | 0.2 | -0.02 | 0.11 | -0.13 | -0.04 | 0.46 | 0.21 | 0.81 |
| Surprise Percentage | 0.2494% | 23.176% | 6.5831% | -20.8202% | 7.2727% | -0.9901% | 5.1643% | -4.7794% | -1.5209% | 23.9583% | 12.6506% | 39.7059% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DVA
2026-08-08 05:07:38
Morningstar analyst Julie Utterback reports on DaVita Inc. (DVA), a major dialysis service provider, stating that the company's shares fell after management maintained its 2026 outlook. The report highlights DaVita's significant market share in the U.S. dialysis sector and its large patient base, primarily served by government payers. The article also provides related analyst reports from other firms with their target price adjustments.
2026-08-08 01:07:34
DaVita Inc. (DVA) saw its stock fall after management maintained its 2026 outlook. Morningstar's senior analyst, Julie Utterback, covers the company, which is a leading provider of dialysis services in the U.S. with a significant market share. The report highlights DaVita's market position and analyst ratings, including a current price of $183.77.
2026-08-07 21:26:16
DaVita Inc. (DVA) stock increased by 1.72% on Friday, closing at $183.77, snapping a four-day losing streak. This performance outpaced the broader market, with the S&P 500 Index rising 0.62% and the Dow Jones Industrial Average rising 0.28% on the same trading day.
2026-08-07 11:20:42
Truist has lowered its price target for DaVita (NYSE: DVA) to $215 from $250, while reiterating a "Hold" rating on the stock. This adjustment comes amidst other analyst actions on DaVita, with some firms raising and others adjusting their price targets, and follows DaVita's recent Q2 2026 earnings report.
2026-08-07 11:07:34
Janus Henderson Group PLC significantly increased its stake in DaVita Inc. by 96.2% during the first quarter, acquiring an additional 18,237 shares to total 37,188 shares valued at approximately $5.7 million. Other institutional investors also adjusted their positions, with institutional ownership now standing at 90.12%. DaVita recently reported strong quarterly earnings, beating estimates with $4.02 EPS on $3.55 billion revenue, and maintained its 2026 adjusted EPS guidance despite some concerns about narrowing margins and reimbursement pressures.
2026-08-07 10:26:16
DaVita HealthCare Partners Inc. stock rose 2.1% in pre-open trading today after TD Cowen upgraded the kidney dialysis provider from Hold to Buy, increasing its price target to $220 from $201. Analysts cited an improving market position, new care modality potential from MOTheR trial results, and the stock's discounted entry point after Q2 2026 results which beat consensus but led to a sharp sell-off due to flat full-year guidance.
